CN108042495A - 一种格列吡嗪脂质纳米粒固体制剂 - Google Patents
一种格列吡嗪脂质纳米粒固体制剂 Download PDFInfo
- Publication number
- CN108042495A CN108042495A CN201711388932.8A CN201711388932A CN108042495A CN 108042495 A CN108042495 A CN 108042495A CN 201711388932 A CN201711388932 A CN 201711388932A CN 108042495 A CN108042495 A CN 108042495A
- Authority
- CN
- China
- Prior art keywords
- glipizide
- lipid nano
- nano particle
- solid
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
实施例 | 平均粒径(nm) | 多分散系数 |
实施例1 | 248.1±7.9 | 0.116±0.015 |
实施例2 | 231.6±5.4 | 0.133±0.020 |
实施例3 | 268.7±6.6 | 0.175±0.019 |
实施例 | 包封率(%) |
实施例1 | 93.7 |
实施例2 | 92.8 |
实施例3 | 94.2 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711388932.8A CN108042495B (zh) | 2017-12-21 | 2017-12-21 | 一种格列吡嗪脂质纳米粒固体制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711388932.8A CN108042495B (zh) | 2017-12-21 | 2017-12-21 | 一种格列吡嗪脂质纳米粒固体制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108042495A true CN108042495A (zh) | 2018-05-18 |
CN108042495B CN108042495B (zh) | 2018-10-12 |
Family
ID=62130721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711388932.8A Active CN108042495B (zh) | 2017-12-21 | 2017-12-21 | 一种格列吡嗪脂质纳米粒固体制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108042495B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151720A (zh) * | 2019-05-09 | 2019-08-23 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
WO2022024127A1 (en) * | 2020-07-29 | 2022-02-03 | Karnak Technologies, Llc | Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105708799A (zh) * | 2016-01-27 | 2016-06-29 | 金银秀 | 一种纳米结构脂质载体药物组合物及其制备方法 |
-
2017
- 2017-12-21 CN CN201711388932.8A patent/CN108042495B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105708799A (zh) * | 2016-01-27 | 2016-06-29 | 金银秀 | 一种纳米结构脂质载体药物组合物及其制备方法 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110151720A (zh) * | 2019-05-09 | 2019-08-23 | 合肥信风科技开发有限公司 | 含非索罗定的药用组合物及其制备方法 |
WO2022024127A1 (en) * | 2020-07-29 | 2022-02-03 | Karnak Technologies, Llc | Pharmaceutical compositions for improved delivery of therapeutic lipophilic actives |
Also Published As
Publication number | Publication date |
---|---|
CN108042495B (zh) | 2018-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vass et al. | Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals | |
TWI289063B (en) | Preparation with a good disintegrating property | |
US9283190B2 (en) | Highly efficient and long-acting slow-release formulation of poorly soluble drugs and preparation method thereof | |
WO2008134557A2 (en) | Solid dosage forms | |
NO341321B1 (no) | Preparat for oral administrering av tamsulosin-hydroklorid og granul med kontrollert frigivelsesformulering omfattende det samme | |
WO2021238978A1 (zh) | 含硝羟喹啉前药的药物组合物及其制备方法和应用 | |
CN102357077B (zh) | 一种包裹难溶性药物的蛋白纳米颗粒及其制备方法 | |
US8962017B2 (en) | Formulation of silymarin with high efficacy and prolonged action and the preparation method thereof | |
CN112915121A (zh) | 一种大麻素纳米胶束制剂及其制备方法 | |
CN108042495B (zh) | 一种格列吡嗪脂质纳米粒固体制剂 | |
CN101283982A (zh) | 非诺贝特纳米混悬剂及其制备方法 | |
US9023388B2 (en) | Formulation of silibinin with high efficacy and prolonged action and the preparation method thereof | |
CN111759816A (zh) | 口服固体纳米晶体缓释组合物及其制备方法 | |
CN106619520A (zh) | 一种右兰索拉唑钠的干混悬剂及其制备方法 | |
CN108201535A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
WO2024083026A1 (zh) | 一种卢美哌隆药物组合物、长效微球缓释制剂及其制备方法 | |
CN109432055A (zh) | 一种聚合物包覆姜黄素共晶/胡椒碱的复合纳米颗粒及其制备和在缓释药物制剂中的应用 | |
TWI311488B (zh) | ||
CN102357076B (zh) | 一种包裹难溶性药物的蛋白纳米颗粒的制备方法 | |
Paul et al. | Pentamidine-loaded poly (D, L-lactide) nanoparticles: physicochemical properties and stability work | |
CN106983734B (zh) | 一种布洛芬缓释胶囊及其制备方法 | |
Zeng et al. | Chitosan coated chlorogenic acid and rutincomposite phospholipid liposomes: Preparation, characterizations, permeability and pharmacokinetic. | |
CN102552143B (zh) | 含普伐他汀钠非诺贝特脂质体的药物组合物及其制备方法 | |
CN111557914A (zh) | 一种包含艾瑞昔布的药物组合物 | |
CN104800191A (zh) | 佐米曲普坦纳米冻干粉及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191023 Address after: 264205 No. 1 South Qingdao Road, Weihai economic and Technological Development Zone, Shandong, China Co-patentee after: Dijia Pharmaceutical Group Co.,Ltd. Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Co-patentee after: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Address before: 264205 -1-4 South Road, Weihai economic and Technological Development Zone, Shandong, Qingdao Co-patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210709 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Dijia Pharmaceutical Group Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. Patentee before: WEIHAI DISU PHARMACEUTICAL Co.,Ltd. Effective date of registration: 20210709 Address after: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee after: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Address before: No.1 Qingdao South Road, Weihai Economic and Technological Development Zone, Shandong Province Patentee before: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Patentee before: Dijia Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A solid preparation of glipizide lipid nanoparticles Effective date of registration: 20220721 Granted publication date: 20181012 Pledgee: Bank of China Limited Weihai Branch Pledgor: DISHA PHARMACEUTICAL GROUP Co.,Ltd. Registration number: Y2022980010828 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |